|
Mar 13
|
13 Best Biotech Stocks To Buy Under $20
|
|
Feb 28
|
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2023 Earnings Call Transcript
|
|
Feb 27
|
BioCryst Pharmaceuticals Full Year 2023 Earnings: EPS Misses Expectations
|
|
Feb 27
|
Q4 2023 BioCryst Pharmaceuticals Inc Earnings Call
|
|
Feb 26
|
BioCryst Pharmaceuticals (BCRX) Q4 2023 Earnings Call Transcript
|
|
Feb 26
|
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
|
|
Feb 26
|
BioCryst Pharmaceuticals Inc (BCRX) Reports Growth in ORLADEYO Revenue and Projects ...
|
|
Feb 26
|
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
|
|
Jan 9
|
BioCryst (BCRX) Moves 25.6% Higher: Will This Strength Last?
|
|
Dec 30
|
BioCryst Pharmaceuticals (NASDAQ:BCRX) investors are sitting on a loss of 48% if they invested a year ago
|
|
Dec 19
|
BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)
|
|
Nov 30
|
J.P. Morgan Recommends These 2 ‘Strong Buy’ Stocks With Over 60% Upside Potential
|
|
Nov 29
|
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina
|
|
Nov 12
|
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) recent 18% pullback adds to one-year year losses, institutional owners may take drastic measures
|
|
Nov 10
|
BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO® (berotralstat)
|
|
Nov 3
|
BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months
|
|
Nov 3
|
BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®
|
|
Nov 3
|
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2023 Earnings Call Transcript
|
|
Nov 3
|
BioCryst Pharmaceuticals (BCRX) Q3 2023 Earnings Call Transcript
|
|
Nov 2
|
BioCryst Pharmaceuticals Inc (BCRX) Reports Q3 2023 Earnings: ORLADEYO Revenue Up by 29.8% YoY
|